Home / Business and Economy / Drug Fees Rise, Consumers May Pay More
Drug Fees Rise, Consumers May Pay More
13 Apr
Summary
- Health Minister approved 2.5% fee hikes for drug manufacturers.
- Industry group warns of supply risks for generic medicines.
- Increased costs may be passed to consumers, impacting prices.
Health Minister Jennifer Carroll MacNeill has authorized a 2.5% increase in fees for drug manufacturers utilizing the Health Products Regulatory Authority (HPRA). This decision was made to avert a potential financial shortfall for the HPRA in 2026. The HPRA, primarily funded by manufacturer fees, sought the increase due to anticipated higher workloads and operational costs, including expanding its remit to cover AI in healthcare.
Medicines For Ireland (MFI), a group representing generic drug manufacturers, has voiced strong objections to the fee hikes. They argue that these additional costs, imposed on an industry with tight margins, could undermine the sustainability of generic medicine supplies and lead to persistently high prices for consumers. MFI chairman Donagh O'Leary highlighted the significant cost pressure on manufacturers unable to adjust prices for inflation.
Officials had advised the minister of the HPRA's challenging financial scenario for 2026, noting inflation and increased costs. The fee increases, which range from €335 to €1,210 per product for testing and classification, and higher for advisory services, were approved in December. While some industry groups did not oppose the increases, MFI expressed opposition due to cost concerns and potential impacts on medicine availability and affordability in Ireland.
